{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:34:06Z","timestamp":1787038446533,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bbadis.2024.167448","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:54:16Z","timestamp":1722974056000},"page":"167448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells"],"prefix":"10.1016","volume":"1870","author":[{"given":"Philipp","family":"K\u00f6nig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Maria","family":"Eichhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloy","family":"Suparman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"B\u00fcckrei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindrich","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-7201","authenticated-orcid":false,"given":"Gerd","family":"Bendas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2024.167448_bb0005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","article-title":"Updates and new options in advanced epithelial ovarian cancer treatment","volume":"137","author":"Kurnit","year":"2021","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.bbadis.2024.167448_bb0010","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbadis.2024.167448_bb0015","article-title":"Epithelial ovarian cancer: review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.bbadis.2024.167448_bb0020","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1002\/jcp.26289","article-title":"Molecular mechanisms of drug resistance in ovarian cancer","volume":"233","author":"Norouzi-Barough","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbadis.2024.167448_bb0025","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2024.167448_bb0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","volume":"201","author":"Murai","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2024.167448_bb0035","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/cas.15207","article-title":"Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy","volume":"113","author":"Taniyama","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbadis.2024.167448_bb0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41416-021-01364-3","article-title":"Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers","volume":"125","author":"Takashima","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2024.167448_bb0045","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/epi-2017-0019","article-title":"Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer","volume":"9","author":"He","year":"2017","journal-title":"Epigenomics"},{"key":"10.1016\/j.bbadis.2024.167448_bb0050","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.18632\/oncotarget.6413","article-title":"Epigenetic inactivation of the putative DNA\/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs","volume":"7","author":"Nogales","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2024.167448_bb0055","first-page":"1944","article-title":"Overcoming resistance to DNA-targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors, clinical cancer research an official journal of the American association for","volume":"24","author":"Tang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2024.167448_bb0060","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbadis.2024.167448_bb0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Sig. Transduct. Target Ther."},{"key":"10.1016\/j.bbadis.2024.167448_bb0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2024.167448_bb0075","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s41416-021-01560-1","article-title":"Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response","volume":"125","author":"Willis","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2024.167448_bb0080","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41416-020-01199-4","article-title":"SLFN11 informs on standard of care and novel treatments in a wide range of cancer models","volume":"124","author":"Winkler","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2024.167448_bb0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.23761","article-title":"Chemotherapy induced DNA damage response: convergence of drugs and pathways","volume":"14","author":"Woods","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbadis.2024.167448_bb0090","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1111\/febs.13387","article-title":"DNA damage control: regulation and functions of checkpoint kinase 1","volume":"282","author":"Smits","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.bbadis.2024.167448_bb0095","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","article-title":"Coupling of homologous recombination and the checkpoint by ATR","volume":"65","author":"Buisson","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbadis.2024.167448_bb0100","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.bbadis.2024.167448_bb0105","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.leukres.2017.09.005","article-title":"Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia","volume":"61","author":"Webster","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bbadis.2024.167448_bb0110","first-page":"4371","article-title":"Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors, journal of clinical oncology official journal of the American society of","volume":"34","author":"Leijen","year":"2016","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.bbadis.2024.167448_bb0115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.biopha.2012.11.011","article-title":"Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines","volume":"67","author":"Januchowski","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbadis.2024.167448_bb0120","first-page":"414","article-title":"Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues","volume":"47","author":"Behrens","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2024.167448_bb0125","first-page":"447","article-title":"Drug-adapted cancer cell lines as preclinical models of acquired resistance","volume":"2","author":"Michaelis","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bbadis.2024.167448_bb0130","author":"Industrial Biotechnology Centre"},{"key":"10.1016\/j.bbadis.2024.167448_bb0135","article-title":"Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors, NAR","volume":"4","author":"Golder","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.bbadis.2024.167448_bb0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.bbadis.2024.167448_bb0145","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3390\/biom9120788","article-title":"The impact of integrin-mediated matrix adhesion on cisplatin resistance of W1 ovarian cancer cells","volume":"9","author":"Wantoch von Rekowski","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbadis.2024.167448_bb0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-023-04548-1","article-title":"A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis","volume":"92","author":"K\u00f6nig","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167448_bb0155","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbadis.2024.167448_bb0160","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature24060","article-title":"BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing","volume":"550","author":"Zhao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2024.167448_bb0165","doi-asserted-by":"crossref","first-page":"94","DOI":"10.15252\/embr.201540964","article-title":"SLFN11 inhibits checkpoint maintenance and homologous recombination repair","volume":"17","author":"Mu","year":"2016","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bbadis.2024.167448_bb0170","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","article-title":"SLFN11 blocks stressed replication forks independently of ATR","volume":"69","author":"Murai","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbadis.2024.167448_bb0175","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015654118","article-title":"SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR\/CHK1 inhibitors","volume":"118","author":"Jo","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2024.167448_bb0180","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbadis.2024.167448_bb0185","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2024.167448_bb0190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13073-021-00952-5","article-title":"Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes","volume":"13","author":"Barnes","year":"2021","journal-title":"Genome Med."},{"key":"10.1016\/j.bbadis.2024.167448_bb0195","first-page":"4196","article-title":"Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines","volume":"52","author":"Yaginuma","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2024.167448_bb0200","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2024.167448_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443924004411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443924004411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T09:30:25Z","timestamp":1764581425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443924004411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0925443924004411"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2024.167448","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2024.167448","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"167448"}}